Ben Ho Park

List of Publications by Year
in descending order

124 papers	14,114 citations	71102 41 h-index	23533 111 g-index
127 all docs	127 docs citations	127 times ranked	21034 citing authors

#	Article	IF	Citations
1	The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science, 2006, 314, 268-274.	12.6	3,130
2	The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 2007, 318, 1108-1113.	12.6	3,049
3	DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature, 2002, 416, 552-556.	27.8	1,126
4	Role of BAX in the Apoptotic Response to Anticancer Agents. Science, 2000, 290, 989-992.	12.6	843
5	The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology and Therapy, 2004, 3, 772-775.	3.4	594
6	Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell, 2003, 3, 89-95.	16.8	378
7	NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming. Molecular Cell, 2011, 44, 609-620.	9.7	356
8	p21 and p27: roles in carcinogenesis and drug resistance. Expert Reviews in Molecular Medicine, 2008, 10, e19.	3.9	346
9	Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. Clinical Cancer Research, 2014, 20, 2643-2650.	7.0	341
10	GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Human Pathology, 2013, 44, 1341-1349.	2.0	192
11	Duel nature of TGF-?? signaling: tumor suppressor vs. tumor promoter. Current Opinion in Oncology, 2005, 17, 49-54.	2.4	161
12	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 993-999.	7.0	152
13	Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2835-2840.	7.1	145
14	The multiple myelomaâ€“associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood, 2008, 111, 856-864.	1.4	137
15	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17773-17778.	7.1	134
16	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research, 2017, 19, 60.	5.0	116
17	Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clinical Cancer Research, 2017, 23, 4716-4723.	7.0	102
18	The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 670-678.	4.9	96

#	Article	IF	Citations
19	Estrogen Receptor Î± Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death. Cancer Research, 2007, 67, 5337-5344.	0.9	94
20	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. Cancer Research, 2014, 74, 2773-2784.	0.9	94
21	A p21-ZEB1 Complex Inhibits Epithelial-Mesenchymal Transition through the MicroRNA 183-96-182 Cluster. Molecular and Cellular Biology, 2014, 34, 533-550.	2.3	92
22	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clinical Biochemistry, 2015, 48, 993-998.	1.9	91
23	Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 288-293.	7.1	86
24	Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-rasâ€“Mediated Transformation. Cancer Research, 2007, 67, 8460-8467.	0.9	85
25	PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System. Clinical Cancer Research, 2013, 19, 5413-5422.	7.0	84
26	Deletion of PTEN Promotes Tumorigenic Signaling, Resistance to Anoikis, and Altered Response to Chemotherapeutic Agents in Human Mammary Epithelial Cells. Cancer Research, 2009, 69, 8275-8283.	0.9	79
27	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology, 2021, 39, 2539-2551.	1.6	78
28	Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 205-216.	2.7	77
29	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget, 2016, 7, 6281-6293.	1.8	76
30	Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nature Communications, 2014, 5, 4961.	12.8	72
31	HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6205-14.	7.1	69
32	Relationship Between Molecular Subtype of Invasive Breast Carcinoma and Expression of Gross Cystic Disease Fluid Protein 15 and Mammaglobin. American Journal of Clinical Pathology, 2011, 135, 587-591.	0.7	65
33	Circulating Tumor DNA: Measurement and Clinical Utility. Annual Review of Medicine, 2018, 69, 223-234.	12.2	65
34	Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2684-93.	7.1	60
35	Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer, 2016, 122, 3015-3023.	4.1	60
36	MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17606-17611.	7.1	56

#	Article	IF	Citations
37	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 4390-4397.	1.6	51
38	Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Human Pathology, 2012, 43, 1003-1011.	2.0	49
39	Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. Cancer Research, 2017, 77, 5602-5613.	0.9	48
40	PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?. Cancer Cell, 2007, 12, 297-299.	16.8	45
41	p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells. Cancer Biology and Therapy, 2004, 3, 221-225.	3.4	44
42	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. Molecular and Cellular Proteomics, 2015, 14, 1959-1976.	3.8	44
43	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 3205-3221.	1.6	43
44	Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 147-154.	2.8	41
45	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. Journal of Clinical Investigation, 2019, 129, 4708-4723.	8.2	41
46	The PIK3CA Gene as a Mutated Target for Cancer Therapy. Current Cancer Drug Targets, 2008, 8, 733-740.	1.6	41
47	Protein Phosphatase 2A Regulates Estrogen Receptor Î± (ER) Expression through Modulation of ER mRNA Stability. Journal of Biological Chemistry, 2005, 280, 29519-29524.	3.4	39
48	Polyamine Analogues Down-regulate Estrogen Receptor Î± Expression in Human Breast Cancer Cells. Journal of Biological Chemistry, 2006, 281, 19055-19063.	3.4	37
49	The role of targeted therapy and biomarkers in breast cancer treatment. Clinical and Experimental Metastasis, 2012, 29, 807-819.	3.3	36
50	High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Research and Treatment, 2018, 168, 695-702.	2.5	35
51	TMSB4Yis a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Oncotarget, 2015, 6, 44927-44940.	1.8	34
52	Single Copies of Mutant KRAS and Mutant PIK3CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation. Cancer Research, 2013, 73, 3248-3261.	0.9	33
53	Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. Endocrinology, 2018, 159, 285-296.	2.8	32
54	Somatic alterations as the basis for resistance to targeted therapies. Journal of Pathology, 2014, 232, 244-254.	4.5	31

#	Article	IF	Citations
55	PIK3CA and KRAS mutations predict for response to everolimus therapy: now thatâ€™s RAD001. Journal of Clinical Investigation, 2010, 120, 2655-2658.	8.2	31
56	AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget, 2015, 6, 14754-14765.	1.8	30
57	Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. JAMA Oncology, 2022, 8, 287.	7.1	27
58	Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices. JCO Clinical Cancer Informatics, 2020, 4, 602-613.	2.1	26
59	Use of cell free DNA in breast oncology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 266-274.	7.4	24
60	Prevalence ofPIK3CAmutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biology and Therapy, 2013, 14, 888-896.	3.4	23
61	p21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biology and Therapy, 2007, 6, 1025-1030.	3.4	22
62	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2021, 39, 2247-2256.	1.6	22
63	NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11583-11588.	7.1	21
64	Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Research and Treatment, 2006, 99, 23-33.	2.5	20
65	G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis. Communications Biology, 2021, 4, 585.	4.4	20
66	A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Science Translational Medicine, 2021, 13, .	12.4	20
67	PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Research and Treatment, 2017, 162, 451-464.	2.5	16
68	BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Breast Cancer Research, 2019, 21, 51.	5.0	16
69	Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 101-109.	7.0	14
70	mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss. Cancer Research, 2013, 73, 5218-5231.	0.9	13
71	A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics, 2015, 15, 318-326.	2.2	13
72	Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Human Pathology, 2014, 45, 1546-1550.	2.0	12

#	Article	IF	Citations
73	A Polycythemia VeraJAK2Mutation Masquerading as a Duodenal Cancer Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1495-1498.	4.9	12
74	Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT. Journal of Clinical Oncology, 2016, 34, e13-e16.	1.6	11
75	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. Journal of Clinical Investigation, 2021, 131, .	8.2	11
76	Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Instituteâ€“Designated Comprehensive Cancer Center. Oncologist, 2021, 26, e1962-e1970.	3.7	11
77	ERpS294 is a biomarker of ligand or mutational ERÎ± activation and a breast cancer target for CDK2 inhibition. Oncotarget, 2017, 8, 83432-83445.	1.8	11
78	Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. JAMA Oncology, 2019, 5, 1506.	7.1	10
79	TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Research and Treatment, 2020, 179, 631-642.	2.5	10
80	Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. Cancers, 2020, 12, 2397.	3.7	10
81	The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer. British Journal of Cancer, 2021, 125, 780-788.	6.4	10
82	A High-Throughput Screen with Isogenic PTEN+/+ and PTENâ^'/â^' Cells Identifies CID1340132 as a Novel Compound That Induces Apoptosis in PTEN and PIK3CA Mutant Human Cancer Cells. Journal of Biomolecular Screening, 2011, 16, 383-393.	2.6	9
83	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget, 2015, 6, 25240-25251.	1.8	9
84	Detection of Cancer DNA in Early Stage and Metastatic Breast Cancer Patients. Methods in Molecular Biology, 2018, 1768, 209-227.	0.9	8
85	Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors. Breast Cancer Research and Treatment, 2020, 181, 297-307.	2.5	8
86	Plasma tumor DNA: on your markers, get set, go!. Annals of Translational Medicine, 2014, 2, 2.	1.7	8
87	PIK3CAmutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biology and Therapy, 2011, 11, 358-367.	3.4	7
88	Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2â€“Targeted Therapies for Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1084-1086.	1.6	7
89	Activating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome. Journal of Proteome Research, 2015, 14, 3882-3891.	3.7	7
90	Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancerâ€”Bad Blood. JAMA Oncology, 2019, 5, 1479.	7.1	7

#	Article	IF	Citations
91	Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR. Clinical Chemistry, 2017, 63, 1370-1376.	3.2	6
92	Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 873-880.	3.8	6
93	Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. JCO Precision Oncology, 2022, , .	3.0	6
94	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Communications Biology, 2021, 4, 862.	4.4	5
95	A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. JCO Clinical Cancer Informatics, 2022, 6, e2100105.	2.1	5
96	Gene Mutation Profiling of Breast Cancers for Clinical Decision Making. JAMA Oncology, 2015, 1, 569.	7.1	3
97	Detecting Plasma Tumor DNA in Early-Stage Breast Cancerâ€"Reply. Clinical Cancer Research, 2015, 21, 3570-3570.	7.0	3
98	ESR1 mutations: PiÃ¨ce de rÃ©sistance. Genes and Diseases, 2016, 3, 124-129.	3.4	3
99	Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Practical Laboratory Medicine, 2018, 12, e00108.	1.3	3
100	PIK3CA Mutations in Hormone Receptorâ€"Positive Breast Cancers. JAMA Oncology, 2018, 4, 1330.	7.1	3
101	Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01905.	1.6	3
102	Needles in a haystack: finding recurrent genomic changes in breast cancer. Breast Cancer Research, 2013, 14, 304.	5.0	2
103	Circulating Tumor DNAâ€"the Potential of Liquid Biopsies. Current Breast Cancer Reports, 2016, 8, 14-21.	1.0	2
104	Personalized postdoctoral fellowship care. Nature Biotechnology, 2018, 36, 900-902.	17.5	2
105	The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. Breast Cancer Research and Treatment, 2019, 174, 401-412.	2.5	2
106	Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 375-379.	4.9	2
107	Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone.. Journal of Clinical Oncology, 2022, 40, 3077-3077.	1.6	2
108	The Impact of Collisions on the Ability to Detect Rare Mutant Alleles Using Barcode-Type Next-Generation Sequencing Techniques. Cancer Informatics, 2017, 16, 117693511771923.	1.9	1

#	Article	IF	Citations
109	Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Clinical Advances in Hematology and Oncology, 2021, 19, 155-161.	0.3	1
110	NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. Oncotarget, 2022, 13, 373-386.	1.8	1
111	The Role of PIK3CA Mutations as A Predictor of Outcomes and A Therapeutic Target. Current Breast Cancer Reports, 2010, 2, 167-173.	1.0	0
112	Circulating Free Tumor DNA (ctDNA): The Real-Time Liquid Biopsy. Cancer Drug Discovery and Development, 2017, , 105-118.	0.4	0
113	A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Research and Treatment, 2018, 170, 425-430.	2.5	0
114	Circulating Cell-Free DNA for Molecular Diagnostics and Therapeutic Monitoring. , 2019, , 89-99.		0
115	OR05-05 Lethal ERÎ±-Dependent Hyperactivation of the Unfolded Protein Response Induces Complete Regression Without Recurrence of Primary and Metastatic Breast Cancer. Journal of the Endocrine Society, 2020, 4, .	0.2	0
116	Variant Interpretation in Patients With Metastatic Breast Cancerâ€"Reply. JAMA Oncology, 2020, 6, 582.	7.1	0
117	ERa-Dependent Lethal Hyperactivation of the Anticipatory Unfolded Protein Response Induces Complete Regression Without Recurrence of Advanced Breast Cancer. Journal of the Endocrine Society, 2021, 5, A981-A982.	0.2	0
118	CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER. Neuro-Oncology, 2020, 22, ii41-ii41.	1.2	0
119	Abstract P1-16-07: A synthetic lethality treatment strategy for p53 mutant breast cancer. Cancer Research, 2022, 82, P1-16-07-P1-16-07.	0.9	0
120	Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer. Cancer Research, 2022, 82, P2-08-15-P2-08-15.	0.9	0
121	Rolling window-based hepatitis toxicity prediction from routine bloodwork in patients undergoing immune checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2022, 40, e13565-e13565.	1.6	0
122	Predicting immune checkpoint inhibitor-related pneumonitis using patient medical information.. Journal of Clinical Oncology, 2022, 40, e13566-e13566.	1.6	0
123	Predicting immune checkpoint inhibitor-related hepatitis using electronic health records of patients.. Journal of Clinical Oncology, 2022, 40, e13564-e13564.	1.6	0
124	Overcoming barriers in academic-industry partnerships to improve predictive modeling in immuno-oncology.. Journal of Clinical Oncology, 2022, 40, e13581-e13581.	1.6	0